Build vs Buy: Clinical Document AI in 2026

Status: Comparison draft for Healthcare RAG hub. Outline locked; body to be drafted with anonymized examples. Target length: 1,500 words. Schema: Comparison + FAQPage. Strategic role: decision-stage content; closest to the call CTA in the buyer journey.

If you're a healthcare CIO or VP Engineering deciding whether to buy a clinical-AI vendor or build, this is the decision framework we walk clients through. We've engaged on both sides — built systems for clients who decided to build, helped buyers evaluate vendors for clients who decided to buy. The choice is not always obvious; it's usually one of three answers.

The three answers

1. Buy. A vendor handles your specific workflow (ambient scribe, prior auth, referral intake). They have a BAA. Their pricing math works at your scale. Your team's edge is operational, not algorithmic.
2. Build. Your workflow is differentiated, your data flow is constrained by IP or BAA scope, or vendor pricing breaks down at your scale. Your team's edge is owning the system end-to-end.
3. Hybrid. Buy the foundation models (Bedrock, Azure OpenAI). Buy components where vendor specialization matters (Textract for OCR, Cohere Rerank). Build the orchestration, the prompts, and the audit log. This is the right answer for most healthcare orgs in 2026.

Most teams default to one extreme. The hybrid path is harder to articulate and often wins on actual outcomes.

When buying is right

You should probably buy when:

• The workflow is narrow and the vendor has demonstrated production deployments at customers similar to you.
• The vendor's BAA scope covers everything you need (sub-processors included).
• The vendor's pricing math works at your projected scale (do the math at 1×, 5×, and 10× your current volume).
• Customization needs are minimal — you can live with their workflow assumptions.
• Your team's current size doesn't support a multi-quarter build plus ongoing operations.

Vendors that fit this profile in 2026 (writer to verify and update):

• Ambient scribe: Abridge, Suki, Nuance DAX, DeepScribe.
• Prior authorization: Cohere Health, Vim, Olive (post-restructuring).
• Referral processing: Healthie, Notable.
• Medical coding: Codametrix, Fathom Health.

When building is right

You should probably build when:

• The workflow is differentiated — you're not buying a workflow, you're encoding domain expertise that doesn't exist in any vendor.
• BAA scope creates dealbreaker carve-outs — vendor cannot cover sub-processors or data flows.
• Per-encounter or per-seat pricing produces cost curves that don't survive your projected volume.
• IP retention matters — fine-tuned models on your data must remain yours, with no shared/aggregated learning.
• You already have engineering capacity (or you're building a moat that justifies adding capacity).

The build path is real engineering work. Plan for:

• 4-12 months to first production deployment (workflow complexity dependent).
• Ongoing engineering investment — model updates, prompt refinement, evaluation, on-call.
• Compliance investment — BAA reviews of every sub-processor, audit log infrastructure, security review.

The hybrid path — what most clients actually need

The hybrid path looks like this:

You buy the AI primitives (where vendor specialization gives you a real advantage) and build the system around them (where workflow fit and IP retention matter). This is what we ship for most healthcare clients.

Internal link to: HIPAA-aligned RAG cornerstone.

A worked example — prior-authorization scenario (illustrative)

A representative scenario: a pharmacy evaluates three vendors before deciding to build. Each vendor offers a "PA-as-a-service" platform with a BAA. The analysis turns on three issues:

1. Pricing. Per-PA pricing at projected volume is 4× the build estimate over 24 months.
2. Workflow fit. Vendor UIs are optimized for payer-side review, not pharmacy-side. The decision authority ends up in the wrong place.
3. IP. Fine-tuned models are trained on aggregate customer data — fine for some workloads, not when the clinical logic is a differentiator.

The hybrid path that resolves this: Bedrock + OpenSearch + custom orchestration wired into the existing case-management UI. Pharmacist remains the decision authority. PHI never leaves AWS BAA scope.

The questions that decide it

When we walk a client through this decision, we ask:

1. Is the workflow narrow enough that a vendor's product fits without compromise?
2. Does the vendor's BAA cover every component without carve-outs?
3. At 5× your current volume, what does vendor pricing look like vs. build cost?
4. Does IP retention matter — would shared/aggregated learning be a problem?
5. Do you already have engineering capacity, or would you have to staff up?
6. What's the cost of being wrong in either direction — vendor lock-in or sunk engineering cost?

The answers point clearly to one of the three paths in roughly 80% of conversations.

What we'd never recommend

A few patterns that show up in client questions and that we walk clients away from:

• "Buy from a vendor without a BAA, route around the gap." Don't. The procurement team will catch it eventually and the rework cost is high.
• "Build everything from scratch including the embedding model." Almost never the right answer for healthcare-sized teams in 2026.
• "Use a vendor for the model and store the data ourselves." Often results in two systems with two BAAs and a shared-fate failure mode. Pick a side.
• "Defer the audit log because the vendor handles it." The audit log is a customer obligation under HIPAA. The vendor's log is not your log.

FAQ

1. How long does the buy-vs-build decision usually take?
2. Can we start with buy and migrate to build later?
3. What if no vendor has a BAA for our specific use case?
4. How do we evaluate vendor accuracy on our own data before committing?
5. What's the smallest team that can run a built system in production?
6. How do we model the 5-year TCO of buy vs. build?

Where we fit

CTA — Cal.com 30-min architecture review framed specifically as "the buy-vs-build call." Link to HIPAA-aligned RAG cornerstone. Link to healthcare AI consulting. Link to case studies index.